Table 3

Single nucleotide polymorphisms (SNPs) associated with smoking cessation with meta-analytic p<10−5, and a candidate SNP (last row) from the dopamine beta-hydroxylase (DBH) locus identified by previous genome-wide association studies (GWAS) on smoking cessation

Chr.Top SNPNearest gene within 50 kbEffect/non-effect alleleORpI2Q stat.N/NimpFreq.Effect direction consistent with previous GWAS
10rs10794613FLJ46361 (5′ region)G/C1.433.41×10−600.513/30.21
3rs13064954CCNL1 (3′ region)A/G1.945.28×10−600.603/20.05
10rs1896376CPMX2 (intron)C/T1.835.71×10−6570.103/20.95
3rs9866141VEPH1 (3′ region)T/C1.887.99×10−600.663/30.06
12rs10861185TXNRD1 (intron)C/A1.299.57×10−6160.313/20.57
10rs727417CPXM2 (intron)C/G1.719.67×10−6380.203/30.94
9rs3025343DBH (5′ region)G/A1.240.015460.163/30.87Yes
  • Analyses were adjusted for age, % of predicted forced expiratory volume in 1 s (FEV1) and principal components for genetic ancestry. Patients who were current smokers were considered as ‘controls’, while patients who were former smokers were considered as ‘cases’.

  • P values < 0.05 are depicted in bold. N/Nimp, number of studies contributing to the meta-analysis/number of studies in which SNP was imputed; I2, heterogeneity index; Q stat., p value for Q statistic; p, p value from the fixed effect meta-analysis; Freq., effect allele frequency in 3441 patients with at least one non-missing phenotype from four cohorts studied; Chr., chromosome.